| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10408360490504952 |
| P698 | PubMed publication ID | 15603511 |
| P50 | author | Pierre Hainaut | Q50585710 |
| P2093 | author name string | Claude Caron de Fromentel | |
| Magali Olivier | |||
| Daniela Maurici | |||
| Severine Seemann | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer | Q45886523 | ||
| A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer | Q45889441 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma | Q47976180 | ||
| Role in tumorigenesis of silent mutations in the TP53 gene. | Q53330401 | ||
| Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. | Q53423951 | ||
| Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. | Q53965077 | ||
| Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. | Q54042399 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73 | Q58073315 | ||
| Kinetic Instability of p53 Core Domain Mutants | Q58322007 | ||
| p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities | Q22003973 | ||
| ASPP proteins specifically stimulate the apoptotic function of p53 | Q24291844 | ||
| A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | Q24530763 | ||
| The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro | Q24802914 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer | Q27851503 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| Surfing the p53 network | Q28032484 | ||
| Definition of a consensus binding site for p53 | Q28207794 | ||
| Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein | Q28238628 | ||
| Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest | Q28270478 | ||
| Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| Cancer. p53, guardian of the genome | Q29615610 | ||
| Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers | Q29616471 | ||
| Nucleolar Arf sequesters Mdm2 and activates p53 | Q29620244 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 | Q29622924 | ||
| Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity | Q30479523 | ||
| Single-chain antibody against the common epitope of mutant p53: isolation and intracytosolic expression in mammalian cells | Q30757715 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. | Q33536674 | ||
| Regulation of the p53 tumor suppressor protein | Q33792315 | ||
| Redox signalling and transition metals in the control of the p53 pathway | Q33800722 | ||
| The role of p53-target genes in human cancer | Q33861549 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. | Q33967914 | ||
| Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients | Q34215120 | ||
| Zinc binding and redox control of p53 structure and function. | Q34367589 | ||
| TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. | Q34372826 | ||
| Microsatellite alterations in plasma DNA of small cell lung cancer patients. | Q34394739 | ||
| Microsatellite alterations in serum DNA of head and neck cancer patients | Q34394745 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth | Q34402080 | ||
| Genotoxic and non-genotoxic pathways of p53 induction | Q34417108 | ||
| Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. | Q34443272 | ||
| Inhibiting the p53-MDM2 interaction: an important target for cancer therapy | Q35058579 | ||
| Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives | Q35085457 | ||
| Radical causes of cancer. | Q35097371 | ||
| Decision making by p53: life, death and cancer | Q35116663 | ||
| Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis | Q35168290 | ||
| Why did p53 gene therapy fail in ovarian cancer? | Q35172779 | ||
| DNA damage induces phosphorylation of the amino terminus of p53 | Q35199554 | ||
| An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. | Q35911903 | ||
| Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer | Q36431426 | ||
| Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function | Q36562198 | ||
| Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts | Q36671366 | ||
| Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide | Q37088668 | ||
| Dominant-negative p53 mutations selected in yeast hit cancer hot spots | Q37629547 | ||
| Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke | Q37881326 | ||
| Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. | Q38291171 | ||
| Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. | Q38303407 | ||
| Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. | Q38319417 | ||
| Regulation of the specific DNA binding function of p53 | Q38324290 | ||
| Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments | Q38328861 | ||
| A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain | Q39458140 | ||
| Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. | Q39685569 | ||
| CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties | Q39796556 | ||
| Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants | Q40011883 | ||
| Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients | Q40560199 | ||
| Characterization of the human p53 gene | Q40669877 | ||
| Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. | Q40747748 | ||
| Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model | Q40835797 | ||
| The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. | Q40894474 | ||
| A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy | Q40929887 | ||
| p53-dependent cell death/apoptosis is required for a productive adenovirus infection | Q41009439 | ||
| Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. | Q41063629 | ||
| An information-intensive approach to the molecular pharmacology of cancer. | Q41134023 | ||
| Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice | Q41355839 | ||
| Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer | Q41523293 | ||
| The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. | Q42806263 | ||
| Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. | Q42850882 | ||
| A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. | Q43560472 | ||
| Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay | Q43655919 | ||
| The IARC TP53 database: new online mutation analysis and recommendations to users | Q43714274 | ||
| Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. | Q43740367 | ||
| Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia | Q43905055 | ||
| Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. | Q44266870 | ||
| Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas | Q44270897 | ||
| p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. | Q44362161 | ||
| Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer | Q44362471 | ||
| Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. | Q44380836 | ||
| Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death | Q44382924 | ||
| Radiation enhances the anti-tumor effects of vaccinia-p53 gene therapy in glioma | Q44461360 | ||
| Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis | Q44505593 | ||
| Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer | Q45066172 | ||
| Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). | Q45180301 | ||
| Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer | Q45263174 | ||
| Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy | Q45862912 | ||
| Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity | Q45866779 | ||
| Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene | Q45869215 | ||
| Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors | Q45869523 | ||
| P433 | issue | 5-6 | |
| P304 | page(s) | 551-583 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Critical Reviews in Clinical Laboratory Sciences | Q5186664 |
| P1476 | title | The tumor suppressor gene TP53: implications for cancer management and therapy | |
| P478 | volume | 41 |
| Q42088464 | Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants |
| Q33767881 | Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia |
| Q39939944 | Cysteine-conjugated metabolites of ginger components, shogaols, induce apoptosis through oxidative stress-mediated p53 pathway in human colon cancer cells |
| Q33970628 | EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma |
| Q36682128 | Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma |
| Q24676240 | Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells |
| Q38852727 | Methyl Jasmonate: An Alternative for Improving the Quality and Health Properties of Fresh Fruits. |
| Q40245935 | Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer |
| Q34980673 | Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study |
| Q47122526 | Surgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a phase II study |
| Q34636996 | Targeting p53 by small molecules in hematological malignancies |
| Q42385107 | Understanding the multiple biological aspects leading to myeloma |
| Q24654171 | [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells |
| Q54309795 | [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4]. |
| Q50924369 | p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. |
Search more.